Drugs / SGM-101
Trials 7
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT04315467 | Jul 2020 → Feb 2022 | non-small cell lung carcinoma, pulmonary coin lesion | Sunil Singhal | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT02973672 | Jan 2016 → Apr 2019 | colon carcinoma, malignant pancreatic neoplasm, rectal cancer | Surgimab | Completed | No outcome recorded |
| Phase 24 trials | ||||||
| Phase 2 | NCT06280690 | Jan 2024 → Apr 2025 | colon dysplasia, colorectal cancer | Leiden University Medical Center | Unknown | No outcome recorded |
| Phase 2 | NCT04755920 | Jan 2024 → Feb 2026 | metastatic malignant neoplasm in the brain, rectal cancer | Leiden University Medical Center | Unknown | No outcome recorded |
| Phase 2 | NCT05965817 | Dec 2023 → Mar 2025 | metastasis from malignant tumor of colon | Leiden University Medical Center | Unknown | No outcome recorded |
| Phase 2 | NCT04737213 | Nov 2020 → Nov 2021 | metastasis from malignant tumor of colon | Leiden University Medical Center | Unknown | No outcome recorded |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT04642924 | Oct 2019 → Oct 2021 | rectal cancer | Leiden University Medical Center | Unknown | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 3 | NCT03659448 Comparator | Jun 2019 → Nov 2024 overdue | colorectal cancer | Surgimab | Recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 10 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SGM-101 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03659448 ↗ |
| Modality | Monoclonal antibody | “a fluorochrome-labeled anti-carcinoembryonic antigen (CEA) monoclonal antibody intraoperative imaging agent” NCT03659448 ↗ |
| Route | Intravenous | “SGM-101 was administered intravenously for 30 min to patients 2 or 4 days before surgery” PMID 29361435 ↗ Jan 2018 |
| Target | CEACAM5 | “carcinoembryonic antigen-related cell adhesion molecule type 5 (CEACAM5) receptor-targeted” PMID 36705924 ↗ Jan 2023 |